Exabis Library
Welcome to the e-CCO Library!
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP025: Escalation of medical therapy decreases need for repeat dilatation in Crohn’s anastomatic strictures
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysis
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn’s disease following surgical resection in 240 patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:21 PM by ECCO Administrator
1
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP027: Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn’s disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:20 PM by ECCO Administrator
1
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapy
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:18 PM by ECCO Administrator
1
OP028: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targets
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP029: Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM